Skip to main content
SpringerLink
Log in

Reply to “Residual Tumor Volume, Not Percent Cytoreduction, Matters for Surgery of Neuroendocrine Liver Metastasis”

  • Hepatobiliary Tumors
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kasai Y, Hirose K, Corvera CU, et al. Residual tumor volume discriminates prognosis after surgery for neuroendocrine liver metastasis. J Surg Oncol. 2020;121:330–6.

    Article  PubMed  Google Scholar 

  2. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)—Neuroendocrine and Adrenal Tumors. 2022. https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf.

  3. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)—Neuroendocrine and Adrenal Tumors. 2023. [Unpublished].

  4. Howe JR, Merchant NB, Conrad C, et al. The North American Neuroendocrine Tumor Society Consensus Paper on the surgical management of pancreatic neuroendocrine tumors. Pancreas. 2020;49:1–33.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Howe JR, Cardona K, Fraker DL, et al. The surgical management of small bowel neuroendocrine tumors: consensus guidelines of the North American Neuroendocrine Tumor Society. Pancreas. 2017;46:715–31.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We thank Kasai et al. for their interest in our study on outcomes after cytoreductive hepatectomy for neuroendocrine tumor liver metastases (NETLMs) and the opportunity to respond to their thoughtful comments.

Author information

Authors and Affiliations

  1. Department of Surgery, Mayo Clinic, Rochester, MN, USA

    Hallbera Gudmundsdottir MD & Sean P. Cleary MD, MSc, MPH, FRCSC

  2. Mayo Clinic Comprehensive Cancer Center, Rochester, MN, USA

    Sean P. Cleary MD, MSc, MPH, FRCSC & Thorvardur R. Halfdanarson MD

Authors
  1. Hallbera Gudmundsdottir MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sean P. Cleary MD, MSc, MPH, FRCSC
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Thorvardur R. Halfdanarson MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sean P. Cleary MD, MSc, MPH, FRCSC.

Ethics declarations

Disclosures

Dr. Thor Halfdanarson reports research support from Thermo Fisher Scientific, Advanced Accelerator Applications (a Novartis company), Camurus, Crinetics, and Isotopen Technologien Muenchen (ITM) and consulting or being on the advisory board of Ipsen, TerSera, Advanced Accelerator Applications (a Novartis company), Isotopen Technologien Muenchen (ITM), Crinetics, Viewpoint Molecular Targeting, and Camurus.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gudmundsdottir, H., Cleary, S.P. & Halfdanarson, T.R. Reply to “Residual Tumor Volume, Not Percent Cytoreduction, Matters for Surgery of Neuroendocrine Liver Metastasis”. Ann Surg Oncol 30, 5459–5460 (2023). https://doi.org/10.1245/s10434-023-13839-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-023-13839-z

Search

Navigation